Patents
Sitemap › G01 - Measuring; Testing › G01N - Investigating or analysing materials by determining their chemical or physical properties › G01N 33 - Investigating or analysing materials by specific methods not covered by groups
Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632)
12/2005
12/29/2005WO2005106476A3 Method for diagnosing infectious diseases
12/29/2005WO2005098448A3 Method and biomarkers for detecting tumor endothelial cell proliferation
12/29/2005WO2005091704A3 Magnetic nanoparticles of noble metals
12/29/2005WO2005086830A3 Raman-enhancing, and non-linear optically active nano-sized optical labels and uses thereof
12/29/2005WO2005084283A3 Supersensitive immunoassays
12/29/2005WO2005077978A3 Antibody for diagnosing and treating neuropsychiatric diseases, in particular schizophrenia, depression and bipolar affective disorders
12/29/2005WO2005076011A3 Use of glut1 transporter expressed in blood brain barrier cells for screening for pharmacologically active substances
12/29/2005WO2005074604A3 METHODS OF DETECTING Lp-PLA2 ACTIVITY
12/29/2005WO2005074436A3 Self-assembling split-fluorescent protein systems
12/29/2005WO2005072475A3 Itpks as modifiers of the igfr pathway and methods of use
12/29/2005WO2005072270A3 Methods and compositons for treating cancer
12/29/2005WO2005072161A3 Apparatus and process for sensing target gas species in semiconductor processing systems
12/29/2005WO2005064345A3 Methods and systems for protein and peptide evidence assembly
12/29/2005WO2005061542A3 Detection of cd20 in transplant rejection
12/29/2005WO2005059163A3 Methods, compositions, and kits for analysis of enzyme activity in cells
12/29/2005WO2005058373A3 Methods, program products, and systems for single and multi-agent dosing
12/29/2005WO2005058244A3 Novel anti-dc-sign antibodies
12/29/2005WO2005051178A3 Marker for neuromyelitis optica
12/29/2005WO2005050391A3 System, method and software arrangement utilizing a multi-strip procedure that can be applied to gene characterization using dna-array data
12/29/2005WO2005050207A3 Diffraction grating-based encoded articles for multiplexed experiments
12/29/2005WO2005049790A3 Skn-1 and gsk-3 genes and proteins
12/29/2005WO2005046587A3 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
12/29/2005WO2005043441A8 Method for visualising the adme characteristics of chemical substances
12/29/2005WO2005042765A3 High throughput screening methods for lubricating oil compositions
12/29/2005WO2005037190A3 Multiplex vaccines
12/29/2005WO2005033982A3 Method for simulating the interaction of chemical substances and living organisms
12/29/2005WO2005031308A3 Analyzing histamine h4 receptor-mediated effects in whole blood
12/29/2005WO2005016115A3 Biosensors utilizing dendrimer-immobilized ligands and their use thereof
12/29/2005WO2005001411A3 An online flow through microchip for detecting hazardous chemical and biological agents in drinking water
12/29/2005WO2004111608A8 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
12/29/2005WO2004101745A3 NOVEL REGULATORY MECHANISMS OF NF-kappaB
12/29/2005WO2004091384A3 Erbb surface receptor complexes as biomarkers
12/29/2005WO2004084832A3 Measurement of estrogen activity in plants and a composition therefrom
12/29/2005WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
12/29/2005WO2004045544A8 Autocrine growth factor receptor antibodies and methods
12/29/2005WO2004037992A3 Mapk7 as modifier of branching morphogenesis and methods of use
12/29/2005WO2004026820A3 Method for assaying compounds that decrease the activity of poly(adp-ribose)-polymerase (parp)
12/29/2005WO2004015073A3 MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
12/29/2005WO2004005320A3 ErbB-2 RECEPTOR TARGETING PEPTIDE
12/29/2005WO2003088924A3 Phosphoinositide 3-kinase mediated inhibition of gpcrs
12/29/2005WO2003072799A3 Brother of the regulator of imprinted sites (boris)
12/29/2005WO2003071933A3 Novel compositions and methods for cancer
12/29/2005WO2003012122A3 Crystallized structure of type iv collagen nc1 domain hexamer
12/29/2005WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use
12/29/2005WO2002074789A3 Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
12/29/2005WO2002033113A3 Protein-protein interactions in neurodegenerative diseases
12/29/2005US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
12/29/2005US20050289657 Diagnostic and therapeutic use of an atp-binding cassette gene and protein for neurodegenerative diseases
12/29/2005US20050288872 Methods and systems for peak detection and quantitation
12/29/2005US20050288871 Estimating the accuracy of molecular property models and predictions
12/29/2005US20050288870 Number coding for identification of subtypes of coded types of solid phase carriers
12/29/2005US20050288868 Molecular property modeling using ranking
12/29/2005US20050288867 Cell tissue culture management method and system
12/29/2005US20050288866 Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
12/29/2005US20050288865 Peptide and protein identification method
12/29/2005US20050288864 Intracellular antibodies
12/29/2005US20050288848 Method and apparatus for measuring oil aeration of an engine
12/29/2005US20050288602 Device and method for determining respiratory quotient without measuring lung ventilation
12/29/2005US20050288489 Voltage-dependent calcium channel beta subunit functional core
12/29/2005US20050288488 Ah receptor cDNA and genetically engineered cells for detecting agonists to the Ah receptor
12/29/2005US20050288487 Human mast cell-expressed membrane proteins
12/29/2005US20050288247 Inducible inactivation of synaptic transmission
12/29/2005US20050288217 Method for enhancing or inhibiting insulin-like growth factor-I
12/29/2005US20050288216 Novel transformed cell, method of screening antiaging agent and antiaging agents
12/29/2005US20050288212 Components of the presenilin-complex
12/29/2005US20050287682 Dissolvable films and methods including the same
12/29/2005US20050287681 proteins and DNAs in a specimen react highly efficiently with captors fixed to a piece of metal to improve the sensitivity of detection of the target substance; magnetic force and also plasmon resonance that is highly sensitive; marker genes
12/29/2005US20050287680 Multianalyte assay method
12/29/2005US20050287676 Rapidly evaluating metal hydrides for concentration; mass spectrometry, spectroscopy and gas chromatography; sodium alanate
12/29/2005US20050287675 Sample of fiber with binder such as polyacrylic acid crosslinked with triethanolamine is subjected to infrared spectroscopy to generate a spectral analysis, determining a binder cure ratio of the binder in the sample using the spectral analysis
12/29/2005US20050287674 Labeling proteins with dyes that are insoluble or only sparingly soluble in water
12/29/2005US20050287673 Reactor mixing
12/29/2005US20050287664 Cellular proliferation control factors
12/29/2005US20050287663 DNA encoding human alpha and beta subunits of neuronal nicotinic acetylcholine receptor, cells transformed therewith, and a recombinant cell line expressing a functional human alpha7 subunit of neuronal nicotinic acetylcholine receptor
12/29/2005US20050287662 Helper-free stocks of recombinant adeno-associated virus vectors
12/29/2005US20050287631 Compositions and methods related to a dimeric MHC class I and II-Like molecule (dsMHCI and dsMHCII)
12/29/2005US20050287623 Method for detecting reactive metabolites using stable-isotope trapping and mass spectroscopy
12/29/2005US20050287622 A peptide substrate for use as site of botulinum or tetnaus neurotoxin protease action and in identifying modulator which inhibit neurotoxic activity; prevention and treatment of food poisoning; fluorescence resonant energy transfer assay
12/29/2005US20050287621 Chip and apparatus for acetylcholinesterase inhibitor detection and method for using thereof
12/29/2005US20050287619 Method and reagent for measuring cholesterol in high-density lipoproteins
12/29/2005US20050287618 Labeling or detecting of immobilized poly(amino acids), including peptides, polypeptides and proteins, on membranes and other solid supports;
12/29/2005US20050287616 Method of assaying denaturation of proteins
12/29/2005US20050287615 Screening assay to identify inhibitors of the murd enzyme using an activator-independent murd enzyme
12/29/2005US20050287614 Assay for detecting an analyte containing or labelled with a haem moiety
12/29/2005US20050287613 Polyclonal-polyclonal ELISA assay for detecting N-terminus-proBNP
12/29/2005US20050287612 CARD-4 molecules and uses thereof
12/29/2005US20050287611 MHC bridging system for detecting CTL-mediated lysis of antigen presenting cells
12/29/2005US20050287610 Method for detecting the presence or risk of prostate cancer by detecting products of psa or klk2
12/29/2005US20050287609 Methods and compositions for detection of equine tapeworm infections
12/29/2005US20050287608 Diagnostic methods for protein profiling
12/29/2005US20050287607 Methods and compositions for identification of antigen-specific B cell populations
12/29/2005US20050287606 T1 receptor-like ligand I
12/29/2005US20050287604 Maternal antibodies as fetal cell markers to identify and enrich fetal cells from maternal blood
12/29/2005US20050287603 Modulation of bone development
12/29/2005US20050287602 Transfecting a eukaryotic cell with nucleotide sequence, contacting cell with a candidate compound; determining distribution of expressed protein in cell by detecting the distribution of detectable moiety in cell
12/29/2005US20050287601 Diagnostics and therapeutics for macular degeneration-related disorders
12/29/2005US20050287600 Method for screening for agents preventing aggregation of potentially amyloidogenic proteins
12/29/2005US20050287599 Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
12/29/2005US20050287598 specific, high flow-through, and cost-effective assay for testing sample materials for the presence of a pathogenic protein including transthyretin and prion protein; sample is treated with a compound, e.g. a metalloendopeptidase, which selectively hydrolyzes prion protein but not abnormal form
12/29/2005US20050287597 Contacting cell that produces SIRT1 Tat deacetylase polypeptide and an acetylated Tat polypeptide with a test agent; determining level of acetylated Tat polypeptide in cell compared to level of acetylated Tat polypeptide in a control cell; drug screening; human immunodeficiency virus infections
1 ... 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 ... 3937